IDENTIFICATION OF FACTOR-XIIIA-REACTIVE GLUTAMINYL RESIDUES IN THE PROPOLYPEPTIDE OF BOVINE VON-WILLEBRAND-FACTOR

被引:15
作者
TAKAGI, J
AOYAMA, T
UEKI, S
OHBA, H
SAITO, Y
LORAND, L
机构
[1] TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT BIOL SCI, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN
[2] NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL USA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1995年 / 232卷 / 03期
关键词
VON WILLEBRAND FACTOR; PROPOLYPEPTIDE; FACTOR XIIIA; TRANSGLUTAMINASE; DANSYLCADAVERINE;
D O I
10.1111/j.1432-1033.1995.tb20872.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
von Willebrand factor is a large multimeric plasma protein which plays important roles in platelet aggregation, blood coagulation and probably also in the adhesion of endothelial cells. A 100-kDa propeptide, called the propolypeptide of von Willebrand factor (pp-vWF), is generated during biosynthesis. We found that pp-vWF served as a substrate for transglutaminases including human factor XIIIa and guinea pig liver transglutaminase [Usui, T., Takagi, J. & Saito, Y. (1993) J. Biol. Chem. 268, 12311-12316]. As such, it could form cross-linked copolymers with the extracellular matrix protein, laminin, making it all the more likely that pp-vWF plays a role in cell adhesion phenomena [Takagi, J., Sudo, Y., Saito, T. & Saito, Y. (1994) Eur. J. Biochem. 222, 861-867]. In this work, we identified the Gln residues in pp-vWF specifically reacting with blood coagulation factor XIIIa as amine accepters. The fluorescent amine, dansylcadaverine, was employed for labeling the enzyme-reactive sites of the protein. Following partial proteolysis, fragments containing the labeled Gin residues were isolated by passage through an anti-dansyl affinity chromatographic column. Amino acid sequence analyses of the fragments revealed that, out of about 40 Gln residues in pp-vWF, only four could be modified in the factor-XIIIa-catalyzed reaction.
引用
收藏
页码:773 / 777
页数:5
相关论文
共 50 条
[21]   ABNORMAL DEGRADATION OF VON-WILLEBRAND-FACTOR MAIN SUBUNIT IN PULMONARY-HYPERTENSION [J].
LOPES, AAB ;
MAEDA, NY .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (04) :530-536
[22]   ACQUIRED VON-WILLEBRAND DISEASE-ASSOCIATED WITH MULTIPLE-MYELOMA - CHARACTERIZATION OF AN INHIBITOR TO VON-WILLEBRAND-FACTOR [J].
MOHRI, H ;
TANABE, J ;
OHTSUKA, M ;
YOSHIDA, M ;
MOTOMURA, S ;
NISHIDA, S ;
FUJIMURA, Y ;
OKUBO, T .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (06) :561-566
[23]   STRUCTURAL-ANALYSIS OF RECOMBINANT VON-WILLEBRAND-FACTOR - IDENTIFICATION OF HETERO-DIMERS AND HOMO-DIMERS [J].
FISCHER, B ;
MITTERER, A ;
SCHLOKAT, U ;
DENBOUWMEESTER, R ;
DORNER, F .
FEBS LETTERS, 1994, 351 (03) :345-348
[24]   CHARACTERIZATION OF 2 CASES OF ACQUIRED TRANSITORY VON-WILLEBRAND SYNDROME WITH CIPROFLOXACIN - EVIDENCE FOR HEIGHTENED PROTEOLYSIS OF VON-WILLEBRAND-FACTOR [J].
CASTAMAN, G ;
LATTUADA, A ;
MANNUCCI, PM ;
RODEGHIERO, F .
AMERICAN JOURNAL OF HEMATOLOGY, 1995, 49 (01) :83-86
[25]   VON-WILLEBRANDS DISEASE - LABORATORY INVESTIGATION USING AN IMPROVED FUNCTIONAL ASSAY FOR VON-WILLEBRAND-FACTOR [J].
FAVALORO, EJ ;
GRISPO, L ;
DINALE, A ;
BERNDT, M ;
KOUTTS, J .
PATHOLOGY, 1993, 25 (02) :152-158
[26]   ABSENCE OF INCORPORATION OF PLASMA VON-WILLEBRAND-FACTOR INTO PORCINE PLATELET ALPHA-GRANULES [J].
ROUSSI, J ;
DROUET, L ;
SIGMAN, J ;
VAIMAN, M ;
PIGNAUD, G ;
BONNEAU, M ;
MASSE, JM ;
CRAMER, EM .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :661-668
[27]   RELEASE OF VON-WILLEBRAND-FACTOR BY CARDIOPULMONARY BYPASS, BUT NOT BY CARDIOPLEGIA IN OPEN-HEART-SURGERY [J].
VALEN, G ;
BLOMBACK, M ;
SELLEI, P ;
LINDBLOM, D ;
VAAGE, J .
THROMBOSIS RESEARCH, 1994, 73 (01) :21-29
[28]   VON-WILLEBRAND-FACTOR AND FIBRINOLYTIC VARIABLES ARE DIFFERENTLY AFFECTED IN THE INSULIN-RESISTANCE SYNDROME [J].
NILSSON, TK ;
BOMAN, K ;
BJERLE, P ;
HALLMANS, G ;
HELLSTEN, G .
JOURNAL OF INTERNAL MEDICINE, 1994, 235 (05) :419-423
[29]   DDAVPS SHORTENING OF THE BLEEDING-TIME SEEMS DUE TO PLASMA VON-WILLEBRAND-FACTOR [J].
BECK, KH ;
BLECKMANN, U ;
MOHR, P ;
KRETSCHMER, V .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 :40-43
[30]   Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects - Direct comparison of commercial ELISA-based von Willebrand factor activity options [J].
Favaloro, EJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) :608-618